PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-24.71%
Negative net income growth while AXSM stands at 2.60%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.01%
D&A growth well above AXSM's 2.56%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
9.00%
SBC growth well above AXSM's 2.86%. Michael Burry would flag major dilution risk vs. competitor’s approach.
715.46%
Slight usage while AXSM is negative at -149.32%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
244.38%
A yoy AP increase while AXSM is negative at -113.13%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
304.81%
Some yoy usage while AXSM is negative at -355.05%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
412.12%
Some yoy increase while AXSM is negative at -6668.58%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
9.59%
Some CFO growth while AXSM is negative at -7.71%. John Neff would note a short-term liquidity lead over the competitor.
100.00%
Lower CapEx growth vs. AXSM's 218.89%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have mild expansions while AXSM is negative at -118892840.79%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-4.76%
We cut debt repayment yoy while AXSM is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-85.80%
Negative yoy issuance while AXSM is 1644093650.53%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.